{"nctId":"NCT00944710","briefTitle":"Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old","startDateStruct":{"date":"2009-08"},"conditions":["Amblyopia"],"count":73,"armGroups":[{"label":"Intensified treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atropine","Device: Plano lens"]},{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atropine"]}],"interventions":[{"name":"Atropine","otherNames":[]},{"name":"Plano lens","otherNames":[]},{"name":"Atropine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMajor Eligibility Criteria for Run-in Phase\n\n* Age 3 to \\< 8 years\n* Amblyopia associated with strabismus, anisometropia, or both\n* Visual acuity in the amblyopic eye between 20/50 and 20/400 inclusive\n* Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \\>3 logMAR lines\n* Amblyopia treatment within the past 6 months subject to the following stipulations:\n\n  * No more than 6 weeks of any amblyopia treatment other than spectacles (except for patients being treated with atropine who are entering the study on treatment)\n  * No simultaneous treatment with patching and atropine\n  * No use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D\n  * Maximum level of treatment within the past 6 months:\n\n    * Patching: up to 2 hours daily\n    * Atropine: up to once daily\n* Wearing spectacles with optimal correction (if amblyopic eye acuity is 20/80 or better, then VA must be stable in glasses; if amblyopic eye acuity is 20/100 or worse, then spectacles and atropine can be initiated simultaneously).\n* Hypermetropia and spectacle correction in sound eye of +1.50 D or more\n\nEligibility Criteria for Randomization:\n\n* Amblyopic eye acuity of 20/40 to 20/160 with an inter-ocular difference of \\>2 lines, or amblyopic eye acuity of 20/32 with 3 lines of IOD.\n* Compliance with weekend atropine treatment based on investigator judgment.\n\nExclusion Criteria:\n\n* Currently using vision therapy or orthoptics\n* Ocular cause for reduced visual acuity (nystagmus per se does not exclude the patient if the above visual acuity criteria are met)\n* Prior intraocular or refractive surgery\n* Known allergy to atropine or other cycloplegic drugs\n* Down Syndrome present","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"7 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Distribution of 10-week Amblyopic-Eye Visual Acuity","description":"The masked 10-week amblyopic eye visual acuity scores were tabulated for both treatment groups, and included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) with no imputation for missing data.\n\nThe primary outcome analysis followed the \"intent-to-treat\" principle. Therefore, data from randomized participants were included in the analysis regardless of whether the assigned treatment was actually received or whether they deviated from treatment against protocol. In addition, randomized participants who were found to be ineligible upon subsequent review of enrollment data were included in the primary outcome analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Group Comparison of the Proportion of Participants Who Achieved 20/25 or Better Visual Acuity at 10 Weeks Since Randomization","description":"The proportion of participants who achieved 20/25 or better visual acuity since randomization was computed at the 10-week outcome.\n\nThe secondary outcome analysis was a treatment group comparison of the proportion of participants whose 10-week masked amblyopic eye visual acuity was 20/25 or better since randomization. The analysis included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) according to the principles specified in the primary outcome analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization","description":"The proportion of participants who improved at least 2 logMAR lines since randomization was computed at the 10-week outcome.\n\nThe secondary outcome analysis was a treatment group comparison of the proportion of participants whose 10-week masked amblyopic eye visual acuity improved at least 2 logMAR lines since randomization using logistic regression, adjusting for visual acuity at randomization. The analysis included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) according to the principles specified in the primary outcome analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Spectacle Compliance at 10 Weeks by Treatment Group","description":"The distribution of compliance with prescribed treatment was tabulated for the 10-week outcome. Compliance was evaluated as excellent (\\>75%), good (51%-75%), fair (26%-50%), or poor (\\<26%) based on discussions with the parent and by reviewing study calendars maintained by the parent, who recorded the frequency of atropine administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Spectacle Compliance by Treatment Group","description":"The distribution of compliance with prescribed treatment was tabulated for the 10-week outcome and as averaged scores across all study follow-up visits. Compliance was evaluated as excellent (\\>75%), good (51%-75%), fair (26%-50%), or poor (\\<26%) based on discussions with the parent and by reviewing study calendars maintained by the parent, who recorded the frequency of atropine administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Atropine Compliance at 10 Weeks by Treatment Group","description":"The distribution of compliance with prescribed treatment was tabulated for the 10-week outcome. Compliance was evaluated as excellent (\\>75%), good (51%-75%), fair (26%-50%), or poor (\\<26%) based on discussions with the parent and by reviewing study calendars maintained by the parent, who recorded the frequency of atropine administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Atropine Compliance by Treatment Group","description":"The distribution of compliance with prescribed treatment was tabulated for the 10-week outcome and as averaged scores across all study follow-up visits. Compliance was evaluated as excellent (\\>75%), good (51%-75%), fair (26%-50%), or poor (\\<26%) based on discussions with the parent and by reviewing study calendars maintained by the parent, who recorded the frequency of atropine administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean 10-week Amblyopic-Eye Visual Acuity","description":"The primary outcome analysis was a treatment group comparison of the masked 10-week amblyopic eye visual acuity using an analysis of covariance (ANCOVA) model, adjusting for visual acuity at randomization. The analysis included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) with no imputation for missing data.\n\nThe primary outcome analysis followed the \"intent-to-treat\" principle. Therefore, data from randomized participants were included in the analysis regardless of whether the assigned treatment was actually received or whether they deviated from treatment against protocol. In addition, randomized participants who were found to be ineligible upon subsequent review of enrollment data were included in the primary outcome analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.22"},{"groupId":"OG001","value":"0.37","spread":"0.23"}]}]}]},{"type":"PRIMARY","title":"Distribution of the Change in Amblyopic-Eye Visual Acuity","description":"The change in 10-week amblyopic eye visual acuity scores since randomization was tabulated for both treatment groups, and included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) with no imputation for missing data.\n\nThe primary outcome analysis followed the \"intent-to-treat\" principle. Therefore, data from randomized participants were included in the analysis regardless of whether the assigned treatment was actually received or whether they deviated from treatment against protocol. In addition, randomized participants who were found to be ineligible upon subsequent review of enrollment data were included in the primary outcome analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change in Amblyopic-Eye Visual Acuity at 10 Weeks From Randomization","description":"The change in 10-week amblyopic eye visual acuity was computed for both treatment groups and included data from 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) with no imputation for missing data.\n\nThe primary outcome analysis followed the \"intent-to-treat\" principle. Therefore, data from randomized participants were included in the analysis regardless of whether the assigned treatment was actually received or whether they deviated from treatment against protocol. In addition, randomized participants who were found to be ineligible upon subsequent review of enrollment data were included in the primary outcome analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.1"},{"groupId":"OG001","value":"1.1","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Distribution of Interocular Difference at 12-week Exam","description":"Distribution of Interocular Difference Between Eyes at 12-week Exam","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Interocular Difference at 12-week Exam","description":"Mean Interocular Difference Between Eyes at 12-week Exam","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.6"},{"groupId":"OG001","value":"3.3","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Distribution of 12-week Fellow-Eye Visual Acuity","description":"Following the 10-week primary outcome exam, participants discontinued the randomized treatment and returned 2 weeks later for a 12-week visit to measure off-treatment fellow-eye visual acuity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Fellow-Eye Visual Acuity at 12-week Exam","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.09"},{"groupId":"OG001","value":"0.02","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Distribution of Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.9"},{"groupId":"OG001","value":"0.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Distribution of Baseline Characteristics at the 10-week Outcome","description":"The number of participants was tabulated by treatment group within categorical levels of prespecified baseline subgroup factors for participants with 10-week visual acuity exams completed between 8 to 15 weeks (inclusive) according to principles specified in the primary outcome analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Amblyopic Eye Visual at Randomization According to Baseline Characteristics for 10-week Outcome","description":"Mean amblyopic eye visual acuity at randomization was computed by treatment group within categorical levels of prespecified baseline subgroup factors. The analysis included data from participants with 10-week exams completed between 8 to 15 weeks (inclusive) according to the principles specified in the primary outcome analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.19"},{"groupId":"OG001","value":"0.46","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.19"},{"groupId":"OG001","value":"0.51","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.19"},{"groupId":"OG001","value":"0.49","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"0.18"},{"groupId":"OG001","value":"0.43","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"0.22"},{"groupId":"OG001","value":"0.48","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.13"},{"groupId":"OG001","value":"0.58","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.21"},{"groupId":"OG001","value":"0.42","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.18"},{"groupId":"OG001","value":"0.50","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.21"},{"groupId":"OG001","value":"0.48","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.23"},{"groupId":"OG001","value":"0.46","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.13"},{"groupId":"OG001","value":"0.35","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.20"},{"groupId":"OG001","value":"0.56","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.23"},{"groupId":"OG001","value":"0.38","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.23"},{"groupId":"OG001","value":"0.51","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.12"},{"groupId":"OG001","value":"0.53","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.18"},{"groupId":"OG001","value":"0.47","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"0.20"},{"groupId":"OG001","value":"0.49","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.18"},{"groupId":"OG001","value":"0.51","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.17"},{"groupId":"OG001","value":"0.45","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.25"},{"groupId":"OG001","value":"0.47","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Treatment Comparison of Mean Amblyopic Eye Visual Acuity Change at 10-weeks According to Baseline Characteristics","description":"A treatment comparison of mean amblyopic eye visual acuity change since randomization was performed at the 10-week outcome according to categorical levels of prespecified baseline subgroup factors. The analysis included data from participants with 10-week exams completed between 8 to 15 weeks (inclusive) according to the principles specified in the primary outcome analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.0"},{"groupId":"OG001","value":"1.2","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.0"},{"groupId":"OG001","value":"1.1","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.1"},{"groupId":"OG001","value":"1.1","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.2"},{"groupId":"OG001","value":"1.0","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.8"},{"groupId":"OG001","value":"1.3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"04","spread":"1.5"},{"groupId":"OG001","value":"0.7","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.3"},{"groupId":"OG001","value":"1.2","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.5"},{"groupId":"OG001","value":"2.4","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.9"},{"groupId":"OG001","value":"0.6","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.7"},{"groupId":"OG001","value":"1.0","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.3"},{"groupId":"OG001","value":"1.5","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.3"},{"groupId":"OG001","value":"1.3","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.1"},{"groupId":"OG001","value":"0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.1"},{"groupId":"OG001","value":"1.7","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.9"},{"groupId":"OG001","value":"1.0","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.1"},{"groupId":"OG001","value":"0.6","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.7"},{"groupId":"OG001","value":"1.2","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.0"},{"groupId":"OG001","value":"1.7","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.3"},{"groupId":"OG001","value":"1.2","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.8"},{"groupId":"OG001","value":"0.5","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.3"},{"groupId":"OG001","value":"1.0","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.2"},{"groupId":"OG001","value":"1.0","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.9"},{"groupId":"OG001","value":"1.3","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.1"},{"groupId":"OG001","value":"1.3","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Distribution of Amblyopic-Eye Visual Acuity at Best Outcome Visit","description":"Participants in both groups who have improved by one or more lines from randomization to the 10-week outcome exam will continue in the study and visits will occur every 10 weeks until no improvement of one or more lines from the previous visit. The distribution of best post-randomization (10 weeks or later) visual acuity scores in the amblyopic eye was tabulated for both treatment groups using the initial visual acuity score (if a retest was obtained.)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Amblyopic-Eye Visual Acuity at Best Outcome Visit","description":"Participants in both groups who have improved by one or more lines from randomization to the 10-week outcome exam will continue in the study and visits will occur every 10 weeks until no improvement of one or more lines from the previous visit. A treatment comparison of mean amblyopic eye visual acuity at the visit of best post-randomization visual acuity (10 weeks or later) was performed using an analysis of covariance, adjusting for amblyopic eye visual acuity at randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.23"},{"groupId":"OG001","value":"0.29","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Distribution of Change in Amblyopic-Eye Visual Acuity From Randomization to Best Outcome Visit","description":"Participants in both groups who have improved by one or more lines from randomization to the 10-week outcome exam will continue in the study and visits will occur every 10 weeks until no improvement of one or more lines from the previous visit. The distribution of change in best post-randomization (10 weeks or later) visual acuity in the amblyopic eye since randomization was tabulated for both treatment groups using the initial visual acuity score (if a retest was obtained.)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Amblyopic-Eye Visual Acuity at Best Outcome Visit","description":"Participants in both groups who have improved by one or more lines from randomization to the 10-week outcome exam will continue in the study and visits will occur every 10 weeks until no improvement of one or more lines from the previous visit. The mean change in amblyopic eye visual acuity since randomization was computed for both treatment groups based on the visit of best post-randomization visual acuity (10 weeks or later) using the initial visual acuity score (if a retest was obtained.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.2"},{"groupId":"OG001","value":"1.9","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines Based on Visual Acuity at Best Outcome Visit","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Randot Preschool Stereoacuity Score at 12 Weeks","description":"Distribution of Randot Preschool Stereoacuity Score at 12 Weeks; Participants with a Randot Preschool test of \\>800 seconds of arc were classified as having a stereoacuity of 3000 seconds of arc if the Titmus fly test was positive or as nil if the Titmus fly test was negative.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Randot Preschool Stereoacuity Scores at 12 Weeks for Participants With Anisometropic Amblyopia","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Light Sensitivity","New ocular deviation or worsening of preexisting deviation by at least 10 PD"]}}}